Early onset of menstruation associated with higher risk of type 2 diabetes: Large-scale study confirms association may be partially mediated by body mass index
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It’s been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index (BMI) may mediate this association. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).
Type 2 diabetes mellitus has become one of the most common diseases worldwide. In 2015, it affected nearly 8.8% of people aged 20 to 79 globally, and by 2040, it is expected to affect 10.4%. With so many people affected, it is not surprising how much research has been devoted to identifying determinants of the disease in order to prevent its development. Various lifestyle and environmental factors have already been confirmed, but there is also growing evidence pointing to some physiologic factors.
A new study analyzing more than 15,000 postmenopausal women in China has found that women who begin menstruating at an earlier age have a higher risk of developing type 2 diabetes. More specifically, each year of delay in menarche age correlated with a 6% lower risk of type 2 diabetes.
Although this is not the first study to suggest the association between menarche and diabetes, it provides added evidence regarding the increased risk, as well as the fact that BMI can partially mediate the association and the proportion of that effect is 28%.
“This study of rural Chinese women indicates that the average age of menarche is delayed relative to western countries at 16.1 years and is linked with lower risk of type 2 diabetes. Earlier onset of menses (14 y) was associated with diabetes in later life, likely driven by adult BMI. Other factors such as nutrition and BMI in childhood may also play a role in this association,” says Dr. Stephanie Faubion, NAMS medical director.
Source: Read Full Article
